据悉，于本联合公告日期，要约人为一间由长虹集团直接拥有的特殊目的公司(而长虹集团由绵阳市国 资委及四川省财政厅分别持有90%及10%)。作为四川长虹的单一最大股东，长虹集团对四川长虹董事会 大多数成员的组成实际拥有控制权。因此，四川长虹为长虹集团的附属公司，长虹集团进而控制安健及 长虹香港，包括安健及长虹香港所持普通股。追加内容 本文作者可以追加内容哦 ! 根据建议，倘计划生效，全部计划股份将予以注销，以换取每股计划股份1.223港元的计划代价价格， 较最后交易日普通股每股收市价每股0.920港元溢价约32.93%。于本联合公告日期，计划股份合共约5.8 亿股普通股，计划股份的合共估值为约7.09亿港元。 长虹佳华(03991)及要约人虹图投资有限公司联合公布，于2025年9月22日，要... 长虹佳华(03991)及要约人虹图投资有限公司联合公布，于2025年9月22日，要约人与该公司订立实施协 议，据此要约人要求公司向计划股东提呈建议，倘建议获批准及实施，将使公司被要约人通过计划私有 化，且普通股于联交所的上市地位将被撤销。公司已向联交所申请，自2025年9月23日上午9时正起恢复 普通股于联交所的买卖。 ...

Core Viewpoint - The proposed transaction involves the distribution of Lantu shares to existing shareholders and a merger agreement between Dongfeng Motor Group and Dongfeng Motor Group (Wuhan) Investment Co., aiming to privatize the remaining business and enhance shareholder value through the listing of Lantu on the Hong Kong Stock Exchange [1][2]. Group 1: Proposed Transaction Details - The company has resolved to distribute its Lantu shares to existing shareholders, with Lantu applying for a listing on the Hong Kong Stock Exchange, contingent upon the distribution conditions being met [1]. - H-share shareholders will receive 0.3552608 Lantu H-shares for each H-share held on the record date, along with a cash cancellation price of HKD 6.68 per H-share [2]. - The theoretical total value per H-share in the proposed transaction is approximately HKD 10.85, representing a premium of about 128.90% over the last unaffected trading price of HKD 4.74 [2]. Group 2: Strategic Objectives - The merger aims to further integrate quality resources towards emerging industries, focusing on the development of the new energy vehicle sector and transitioning from fuel vehicles to electric vehicles [3]. - The listing of Lantu is expected to broaden financing channels, enhance brand image, expand overseas operations, and improve corporate governance [3]. Group 3: Market Activity - The company has applied to the Stock Exchange for the resumption of trading of H-shares starting from 9:00 AM on August 25, 2025 [4]. - Dongfeng Company is primarily engaged in the manufacturing and supply of commercial vehicles, passenger vehicles, and electric vehicles, along with related services and products [4].

Core Viewpoint - Kangji Medical Holdings Limited plans to initiate a privatization delisting process with an overall valuation of approximately HKD 11.2 billion [2] Group 1: Privatization Details - The privatization is initiated by a consortium led by founder Zhong Ming, along with Shentu Yinguang, global private equity giant TPG, TPG's NewQuest V Fund, and Qatar Investment Authority's Al-Rayyan Holding [5] - The proposed share cancellation price is HKD 9.25 per share, representing a 21.7% premium over the closing price of HKD 7.6 on June 30, 2025, and exceeding the highest closing price of HKD 8.66 since 2022 [5] - Upon completion of the transaction, Kangji Medical will become a wholly-owned subsidiary of the offeror and will delist from the Hong Kong Stock Exchange [5] Group 2: Financial and Ownership Structure - The offeror consortium currently holds 74.75% of Kangji Medical's shares and has received irrevocable support commitments from some institutional shareholders [6] - After privatization, Zhong Ming and his wife will hold 40% of the ultimate holding company (TopCo) through Fortune Spring ZM and Fortune Spring YG, maintaining their position as the largest shareholders [6] - The funding for the transaction includes HKD 2.08 billion in equity financing and external debt financing, with a total cash consideration of approximately HKD 5.818 billion [6] Group 3: Company Background and Performance - Kangji Medical was established in 2004 and raised HKD 3.6 billion when it listed on the Hong Kong Stock Exchange in 2020, becoming one of the largest healthcare IPOs that year [6] - The company's products cover multiple departments, including obstetrics and gynecology and general surgery, serving over 3,500 hospitals in more than 90 countries and regions, including over 1,000 top-tier hospitals [6] - In 2024, Kangji Medical reported revenue of HKD 1.008 billion and a net profit of HKD 581 million, achieving double growth for five consecutive years, although the growth rate fell below 10% for the first time due to centralized procurement policies [6]

Core Viewpoint - The leading minimally invasive medical device company, Kangji Medical Holdings Limited, is planning to go private through an agreement with Knight Bidco Limited, which will result in the company's delisting from the Hong Kong Stock Exchange [2][4]. Group 1: Privatization Details - The consortium involved in the offer includes notable entities such as the founders, TPG, NewQuest V Fund, and Al-Rayyan Holding, which is fully owned by Qatar Investment Authority [4][9]. - The proposed cancellation price for the shares is set at HKD 9.25 per share, valuing the company at approximately USD 1.4 billion (around HKD 10.99 billion), representing a premium of about 21.7% over the closing price on June 30, 2025 [4][7]. - As of August 13, 2023, Kangji Medical's stock price was HKD 8.50, reflecting a year-to-date increase of 40.28%, although it remains significantly below the IPO price of HKD 13.88 set in June 2020 [4][7]. Group 2: Market Conditions and Company Strategy - The company has faced persistent pressure on its stock price and long-term liquidity issues, limiting its ability to raise funds from the market [7]. - The need to maintain its listing incurs administrative and compliance costs, which, coupled with increased competition and industry uncertainties, has led the company to consider significant investments for sustainable growth [7]. - The necessity of maintaining a public listing has diminished, prompting the decision to pursue privatization [7]. Group 3: Shareholder Dynamics - The founders, Zhong Ming and Shen Tu Yingguang, currently control 52.98% of Kangji Medical and will retain a 40% stake in the ultimate holding company post-privatization, ensuring they remain the largest shareholders [10]. - The acceptance of the privatization proposal by minority shareholders remains uncertain and will depend on future developments [11].

Group 1 - The company, 康基医疗, and the offeror, Knight Bidco Limited, announced a privatization plan to allow the company to focus on long-term strategic decisions, including R&D investments and operational upgrades [1] - The proposed cancellation price is set at HKD 9.25 per share, representing a premium of approximately 21.7% over the closing price of HKD 7.6 as of the undisturbed date (June 30, 2025) [1] - The cancellation price also reflects a premium of about 29.7% over the average closing price of HKD 7.13 per share for the 120 trading days prior to the undisturbed date, and a premium of approximately 47.3% over the average closing price of HKD 6.28 per share for the 360 trading days prior [1] Group 2 - The privatization cash consideration amounts to approximately HKD 58.2 billion, and the offeror does not reserve the right to increase the cancellation price [2] - The offeror is backed by a consortium that includes alternative asset management company TPG [2] - 康基医疗 resumed trading today after being suspended since July 18 [2]

Core Viewpoint - Kangji Medical (9997.HK) is planning to privatize through a cash offer of HKD 9.25 per share, valuing the company at approximately USD 1.4 billion (HKD 11.2 billion) [2] Group 1: Privatization Details - The offer represents a premium of about 9.9% based on the last closing price of HKD 8.42 before suspension on July 17, and a premium of approximately 21.7% based on the closing price of HKD 7.60 on June 30 [2] - An independent board committee has been established to provide voting recommendations to independent shareholders based on an independent financial advisor's report [2] Group 2: Shareholder Structure - The Knight Bidco consortium includes the founders holding 52.98% through Fortune Spring ZM and Fortune Spring YG, and TPG's three funds holding a combined 22.92% [3] - After the transaction, the founders and TPG will hold approximately 40% and 39.6% of the shares in the ultimate holding company, TopCo, respectively [4] Group 3: Company Background and Market Position - Kangji Medical is the largest minimally invasive surgical instrument and consumables platform in China, serving over 3,500 hospitals, including more than 1,000 top-tier hospitals, with a business presence in over 90 countries and regions [4] - The company has faced trading price pressure and liquidity constraints over the past two years, with an average daily turnover rate of only 0.15% in the last 24 months [4] Group 4: Strategic Focus Post-Privatization - Privatization is expected to allow the company to focus on long-term strategic investments rather than short-term performance pressures, with additional resources needed for sales and marketing, innovation technology development, and international market expansion [4]

Group 1 - The privatization offer for Kangji Medical is led by Chairman Zhong Ming, TPG, and Qatar Investment Authority (QIA), with a proposed price of HKD 9.25 per share, valuing the company at approximately USD 1.4 billion [1][2] - The company has faced continuous pressure on its stock price and long-term liquidity issues, which have limited its ability to raise funds from the stock market [2] - The company was listed on the Hong Kong Stock Exchange in June 2020, with an initial offering price of HKD 13.88 per share, but the stock price had dropped to HKD 8.42 per share before the privatization announcement, indicating a significant decline [2] Group 2 - The offerors believe that maintaining the company's listing incurs administrative, compliance, and other costs, which provide limited benefits given the current market conditions and regulatory uncertainties [2] - Following the announcement of the privatization, the stock performance was relatively flat, with minor fluctuations observed on August 13, 2023 [2] - After the privatization, the Zhong couple will retain a 40% stake in the ultimate holding company, maintaining their position as the largest shareholders [1]

Group 1 - The core proposal involves privatizing 康基医疗 (09997) through an agreement under Section 86 of the Companies Ordinance, with the offeror Knight Bidco Limited seeking to present this to shareholders [1] - Upon completion of the proposal, 康基医疗 will become a wholly-owned subsidiary of the offeror, and its shares will be delisted from the Hong Kong Stock Exchange [1] - The proposed cash consideration for shareholders is HKD 9.25 per share, representing a premium of approximately 9.9% over the last closing price of HKD 8.42 [1] Group 2 - The offeror is fully owned by MidCo, which in turn is wholly owned by TopCo, with TopCo being held by a consortium of members [1] - The consortium members hold the following approximate stakes: Fortune Spring ZM (25.53%), Fortune Spring YG (14.47%), TPG Asia VII (24.38%), Keyhole (5.01%), Knight Success (5.69%), NewQuest V (4.56%), and Al-Rayyan Holding (20.36%) [1]

Core Viewpoint - 康基医疗 (09997.HK) is proposing to privatize the company through an agreement under Section 86 of the Companies Ordinance, with Knight Bidco Limited as the offeror [1] Group 1: Privatization Proposal - The proposal involves the company becoming a wholly-owned subsidiary of Knight Bidco Limited, leading to the delisting of its shares from the Hong Kong Stock Exchange [1] - The cancellation price is set at HKD 9.25 per share, representing a premium of approximately 9.9% over the last trading price of HKD 8.42 [1] - The board will appoint an independent financial advisor to provide opinions to the independent board committee regarding the proposal [1] Group 2: Financial and Operational Context - The company faces challenges in raising funds from the equity market due to ongoing pressure on transaction prices and limited liquidity of its shares [1] - Considering the costs associated with being listed, the company believes that maintaining its listing status offers limited benefits [1] - Implementing the privatization proposal is expected to alleviate short-term financial performance pressures and allow the company to focus on strategic goals requiring additional resource allocation for sustainable future growth [1] Group 3: Trading Resumption - The company has applied for the resumption of trading of its shares on the Hong Kong Stock Exchange starting from 9:00 AM on August 13, 2025 [1]

Core Insights - The U.S. government is planning to sell shares of mortgage giants Fannie Mae and Freddie Mac in the secondary market, potentially raising up to $30 billion later this year [3] - The combined valuation of the two companies could reach $500 billion or more, with a possible sale of 5% to 15% of their shares, equating to up to $75 billion [3] - Discussions are ongoing regarding whether the two companies will go public as a single entity or remain separate [3] Group 1 - The largest IPO globally was Saudi Aramco in 2019, raising $29.4 billion, while Alibaba's 2014 IPO remains the largest in U.S. history at $25 billion [3] - In the first half of the year, Nasdaq raised $8.85 billion from IPOs, while the New York Stock Exchange raised $7.52 billion, ranking second and third globally [3] - The Federal Housing Finance Agency's director indicated that the companies could remain in conservatorship while issuing shares [4] Group 2 - Recent meetings at the White House included CEOs from major banks like JPMorgan, Goldman Sachs, and Morgan Stanley to discuss the potential IPO plans for the two companies [4] - The complexity of the potential sale has led some bankers to express skepticism about the tight timeline for the IPO [4] - There are concerns regarding how to maintain government guarantees for the companies while privatizing them, which involves both accounting and legislative challenges [4]